XML 61 R51.htm IDEA: XBRL DOCUMENT v3.26.3
Segment information (Details)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2026
USD ($)
Jun. 30, 2026
USD ($)
Mar. 31, 2026
USD ($)
Sep. 30, 2025
USD ($)
Jun. 30, 2025
USD ($)
Mar. 31, 2025
USD ($)
Sep. 30, 2026
USD ($)
Segment
Sep. 30, 2025
USD ($)
Segment Reporting Information [Line Items]                
Number of operating segments | Segment             1  
Number of reportable segments | Segment             1  
Segment Reporting, CODM, Profit (Loss) Measure, How Used, Description             The CODM assesses performance for the segment based on net loss, which is reported on the condensed consolidated statements of operations and comprehensive loss as net loss. The measure of segment assets is reported on the condensed consolidated balance sheets as total assets. When evaluating the Company’s financial performance, the CODM regularly reviews total revenues, total expenses and research and development expenses by program.  
Collaboration revenue $ 0     $ 0     $ 0 $ 6,941
Less:                
General and administrative (20,856)     (10,945)     (52,056) (31,677)
Total operating expenses (90,362)     (60,138)     (227,828) (158,193)
Loss from operations (90,362)     (60,138)     (227,828) (151,252)
Interest income 4,579     2,681     15,079 8,758
Net loss (85,783) $ (73,127) $ (53,839) (57,457) $ (43,397) $ (41,640) (212,749) (142,494)
Single reportable segment                
Segment Reporting Information [Line Items]                
Collaboration revenue         6,941
Less:                
Other direct research and development 13,265     6,404     31,565 15,081
Indirect research and development 21,062     13,143     57,768 36,593
General and administrative 14,530     6,997     36,652 21,246
Other segment expenses 13,765     7,334     32,077 19,632
Total operating expenses 90,362     60,138     227,828 158,193
Loss from operations (90,362)     (60,138)     (227,828) (151,252)
Interest income 4,579     2,681     15,079 8,758
Net loss (85,783)     (57,457)     (212,749) (142,494)
Single reportable segment | Varegacestat                
Less:                
Direct research and development expenses 12,579     12,495     33,128 39,615
Single reportable segment | IM-1021                
Less:                
Direct research and development expenses 9,578     2,874     19,789 7,669
Single reportable segment | IM-1617                
Less:                
Direct research and development expenses 1,629     5,465     4,496 9,397
Single reportable segment | IM-1340                
Less:                
Direct research and development expenses 1,725     3,322     7,261 4,811
Single reportable segment | IM-3050                
Less:                
Direct research and development expenses $ 2,229     $ 2,104     $ 5,092 $ 4,149